Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Short term Debt (2016 - 2024)

Cytosorbents (CTSO) has disclosed Short term Debt for 7 consecutive years, with $2.5 million as the latest value for Q1 2024.

  • For the quarter ending Q1 2024, Short term Debt changed N/A year-over-year to $2.5 million, compared with a TTM value of $2.5 million through Mar 2024, changed N/A, and an annual FY2023 reading of $2.5 million, changed N/A over the prior year.
  • Short term Debt was $2.5 million for Q1 2024 at Cytosorbents, roughly flat from $2.5 million in the prior quarter.
  • Across five years, Short term Debt topped out at $9.2 million in Q3 2020 and bottomed at $833333.0 in Q3 2023.
  • Average Short term Debt over 3 years is $4.3 million, with a median of $3.3 million recorded in 2020.
  • Peak annual rise in Short term Debt hit 700.0% in 2020, while the deepest fall reached 150.0% in 2020.
  • Year by year, Short term Debt stood at $9.2 million in 2020, then crashed by 72.73% to $2.5 million in 2023, then changed by 0.0% to $2.5 million in 2024.
  • Business Quant data shows Short term Debt for CTSO at $2.5 million in Q1 2024, $2.5 million in Q4 2023, and $833333.0 in Q3 2023.